These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 23808966)

  • 1. Molecular modeling of p38α mitogen-activated protein kinase inhibitors through 3D-QSAR and molecular dynamics simulations.
    Chang HW; Chung FS; Yang CN
    J Chem Inf Model; 2013 Jul; 53(7):1775-86. PubMed ID: 23808966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based 3D-QSAR models and dynamics analysis of novel N-benzyl pyridinone as p38α MAP kinase inhibitors for anticytokine activity.
    Ul-Haq Z; Khan W; Zia SR; Iqbal S
    J Mol Graph Model; 2012 Jun; 36():48-61. PubMed ID: 22534481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3D-QSAR and molecular docking studies on fused pyrazoles as p38α mitogen-activated protein kinase inhibitors.
    Lan P; Huang ZJ; Sun JR; Chen WM
    Int J Mol Sci; 2010 Sep; 11(9):3357-74. PubMed ID: 20957100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular dynamics simulation, free energy calculation and structure-based 3D-QSAR studies of B-RAF kinase inhibitors.
    Yang Y; Qin J; Liu H; Yao X
    J Chem Inf Model; 2011 Mar; 51(3):680-92. PubMed ID: 21338122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic Significance of p38 Isoforms (p38α, p38β, p38γ, p38δ) in Head and Neck Squamous Cell Carcinoma: Comparative Serum Level Evaluation and Design of Novel Peptide Inhibitor Targeting the Same.
    Sahu V; Nigam L; Agnihotri V; Gupta A; Shekhar S; Subbarao N; Bhaskar S; Dey S
    Cancer Res Treat; 2019 Jan; 51(1):313-325. PubMed ID: 29747487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The identification of novel p38α isoform selective kinase inhibitors having an unprecedented p38α binding mode.
    Wrobleski ST; Lin S; Dhar TG; Dyckman AJ; Li T; Pitt S; Zhang R; Fan Y; Doweyko AM; Tokarski JS; Kish KF; Kiefer SE; Sack JS; Newitt JA; Witmer MR; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2013 Jul; 23(14):4120-6. PubMed ID: 23746475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular modeling studies of phenoxypyrimidinyl imidazoles as p38 kinase inhibitors using QSAR and docking.
    Ravindra GK; Achaiah G; Sastry GN
    Eur J Med Chem; 2008 Apr; 43(4):830-8. PubMed ID: 17706839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular modeling on pyrimidine-urea inhibitors of TNF-α production: an integrated approach using a combination of molecular docking, classification techniques, and 3D-QSAR CoMSIA.
    Mouchlis VD; Melagraki G; Mavromoustakos T; Kollias G; Afantitis A
    J Chem Inf Model; 2012 Mar; 52(3):711-23. PubMed ID: 22360289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling the binding affinity of p38α MAP kinase inhibitors by partial least squares regression.
    Basant N; Durante C; Cocchi M; Menziani MC
    Chem Biol Drug Des; 2012 Sep; 80(3):455-70. PubMed ID: 22642504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel strategies for inhibition of the p38 MAPK pathway.
    Zhang J; Shen B; Lin A
    Trends Pharmacol Sci; 2007 Jun; 28(6):286-95. PubMed ID: 17482683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Comprehensive Structural Overview of p38α MAPK in Complex with Type I Inhibitors.
    Astolfi A; Iraci N; Manfroni G; Barreca ML; Cecchetti V
    ChemMedChem; 2015 Jun; 10(6):957-69. PubMed ID: 26012502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological evaluation and structural determinants of p38α mitogen-activated-protein kinase and c-Jun-N-terminal kinase 3 inhibition by flavonoids.
    Goettert M; Schattel V; Koch P; Merfort I; Laufer S
    Chembiochem; 2010 Dec; 11(18):2579-88. PubMed ID: 21108268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3D-QSAR studies of JNK1 inhibitors utilizing various alignment methods.
    Madhavan T; Chung JY; Kothandan G; Gadhe CG; Cho SJ
    Chem Biol Drug Des; 2012 Jan; 79(1):53-67. PubMed ID: 21722320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based virtual screening approach to the discovery of p38 MAP kinase inhibitors.
    Choi H; Park HJ; Shin JC; Ko HS; Lee JK; Lee S; Park H; Hong S
    Bioorg Med Chem Lett; 2012 Mar; 22(6):2195-9. PubMed ID: 22342625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential expression and activation of p38 mitogen-activated protein kinase alpha, beta, gamma, and delta in inflammatory cell lineages.
    Hale KK; Trollinger D; Rihanek M; Manthey CL
    J Immunol; 1999 Apr; 162(7):4246-52. PubMed ID: 10201954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insight into the structural determinants of imidazole scaffold-based derivatives as p38 MAP kinase inhibitors by computational explorations.
    Huang C; Li Y; Ren H; Wang J; Shao L; Zhang S; Li G; Yang L
    Curr Med Chem; 2012; 19(23):4024-37. PubMed ID: 22680637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular modelling studies of sirtuin 2 inhibitors using three-dimensional structure-activity relationship analysis and molecular dynamics simulations.
    Chuang YC; Chang CH; Lin JT; Yang CN
    Mol Biosyst; 2015 Mar; 11(3):723-33. PubMed ID: 25502412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-amino-pyrazoles as potent and selective p38α inhibitors.
    Das J; Moquin RV; Dyckman AJ; Li T; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Newitt JA; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2010 Dec; 20(23):6886-9. PubMed ID: 21035336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined 3D-QSAR modeling and molecular docking study on 1,4-dihydroindeno[1,2-c]pyrazoles as VEGFR-2 kinase inhibitors.
    Zeng H; Zhang H
    J Mol Graph Model; 2010 Aug; 29(1):54-71. PubMed ID: 20471293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular dynamics simulation and free energy calculation studies of the binding mechanism of allosteric inhibitors with p38α MAP kinase.
    Yang Y; Shen Y; Liu H; Yao X
    J Chem Inf Model; 2011 Dec; 51(12):3235-46. PubMed ID: 22097958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.